Related Experiment Video

Updated: Aug 18, 2026

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

Epstein-Barr virus behavior in different populations and implications for control of Epstein-Barr virus-associated

G de-Thé

    Cancer Research
    |February 1, 1976
    PubMed

    Insights

    Epstein-Barr virus (EBV) infection timing varies globally, impacting disease risk. Early childhood EBV infection in Uganda may link to Burkitt

    Area of Science:

    • Epidemiology
    • Virology
    • Public Health

    Background:

    • Epstein-Barr virus (EBV) infection epidemiology shows significant population-based differences.
    • Early childhood EBV infection in Uganda contrasts with later infection in Southeast Asia, where nasopharyngeal carcinoma is prevalent.
    • The timing of EBV infection is hypothesized to influence the risk of EBV-associated diseases, such as Burkitt's lymphoma in Equatorial Africa.

    Purpose of the Study:

    • To analyze the epidemiological variations of Epstein-Barr virus (EBV) infection across different risk populations.
    • To explore the relationship between the timing of EBV infection and the incidence of associated diseases.
    • To propose potential intervention strategies for controlling EBV-associated diseases.

    Main Methods:

    • Comparative epidemiological analysis of EBV infection timing in distinct geographical regions (Uganda vs. Southeast Asia).
    • Review of existing literature on EBV-associated diseases and their correlation with infection timing.
    • Development of a framework for potential intervention strategies.

    Main Results:

    • Significant differences in EBV infection timing were observed between populations.
    • EBV infection occurs significantly earlier in Ugandan children (before 2-3 years) compared to Southeast Asian populations.
    • Early EBV infection in Equatorial Africa is proposed as a risk factor for Burkitt's lymphoma.

    Conclusions:

    • The timing of EBV infection is a critical factor in the epidemiology of EBV-associated diseases.
    • Four intervention strategies are proposed: hygienic measures, EBV vaccination, cofactor intervention (e.g., malaria control for Burkitt's lymphoma), and early detection of high-risk groups.

    More Related Videos

    An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection09:43

    An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

    Published on: March 30, 2018

    Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line09:14

    Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

    Published on: September 28, 2022

    Related Concept Videos

    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    The Tumor Microenvironment02:17

    The Tumor Microenvironment

    Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.